The relationship of host immune cells, cytokine and nitric oxide production to tumor cells in ovarian carcinoma
Keywords:
Ovarian carcinoma, Tumor-associated mononuclear cells, Cytokines, Nitric oxideAbstract
AIMS: This brief review focuses on the current understanding of the complex relationship of tumor-associated mononuclear cells (TAMs) with neoplastic cells, summarizing their immunological efficiency, cytokine profile and production of nitric oxide (NO) in the tumor microenvironment, with current insights on how this might affect tumor growth. DATA SOURCE: Data was obtained through Medline from articles indexed during the last 10 years. The main key words used in the research were: cancer, ovarian cancer, cytokine, nitric oxide (NO), mononuclear cell, lymphocyte, macrophage. SELECTION OF STUDIES AND DATA COLLECTION: 30 studies were reviewed, which contained data regarding the production of cytokines and NO by TAMs or malignant cells, and tried to establish a correlation between these mediators and tumor growth, especially in ovarian carcinoma. DATA SUMMARY: TAMs consist mainly of macrophages and T lymphocytes which present lower proliferative indices and cytotoxicity compared to autologous blood monocytes, although they are able to release various cytokines. The profile of cytokine expression could help to explain both the immunological impairment observed in patients with advanced carcinoma diseases and the potential of TAMs to exert antitumor activity, which makes these cells an attractive target for therapeutic intervention. NO is also produced in the tumor microenvironment. Several reports in animals suggest a tumoricidal role for NO, but in human tumors its role has not been well-established and may change during tumor progression.
Downloads
References
Mantovani A. Biology of disease. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Laboratory Invest 1994;71(1):5-16.
Negus RPM, Stamp GWH, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-34.
Mantovani G, Macciň A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer 1997;71:724-31.
Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signalling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-84.
Bernasconi S, Matteucci C, Sironi M, et al. Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 1995;60:300-7.
Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997;28:321-31.
Schondorf T, Engel H, Lindemann C, Kolhagen H, Von Rucker AA, Mallman P. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunol Immunother 1997;44:88-96.
Melani C, Pupa SM, Stoppacciaro A, et al. An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. Int J Cancer 1995;62:572-8.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992;13(7):265-70.
Goedegebuure PS, Douville CC, Doherty JM, et al. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Cell Immunol 1997;175:150-6.
Negus RPM, Stamp GWH, Relf MG et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95:2391-6.
Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL. Expression of mRNA for cytokines in tumour-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992;51:573-80.
Naylor MS, Stamp GWH, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest 1993;91:2194-2206.
Chatwal VJS, Moochhala SM, Chan STF, Ngoi SS. Nitric oxide and cancer. Medical Hypotheses 1996;46:21-4.
Oshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation Res 1994;305:253-64.
Liu RH, Hotchkiss JH. Potential genotoxicity of chronically elevated nitric oxide: a review. Mut Res 1995;339:73-89
Bussolino F, Albini A, Camussi G, et al. Role of soluble mediators in angiogenesis. Eur J Cancer 1996;32A(14):2401-12.
Yim CY, Bastian NR, Smith JC, Hibbs Jr JB, Samlowski WE. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res 1993;53:5507-11.
Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci 1994;91:9407-11.
Edwards P, Cendan JC, Topping DB, et al. Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J Surg Res 1996;63:49-52.
Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997;11:443-8.
Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-4.
Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol 1996;59:797-803.
Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992;149(8):2709-14.
Liew FY. Interactions between cytokines and nitric oxide. Adv Neuroimmunol 1995;5:201-9.
Rojas A, Delgado R, Glaría L, Palacios M. Monocyte chemotactic protein-1 inhibits the induction of nitric oxide synthase in J774 cells. Biochem Biophys Res Commun 1993;196(1):274-9.
Otsuka Y, Nagano K, et al. Inhibition of neutrophil migration by tumor necrosis factor. Ex vivo and in vivo studies in comparison with in vitro effect. J Immunol 1990;145:2639-43.
Hechtman DH, Cybulsky MI, Fuchs HJ, Baker JB, Gimbrone Jr MA. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991;147:883-92.
Cunha FQ, Tamashiro WMSC. Tumour necrosis factor-alpha and interleukin-8 inhibit neutrophil migration in vitro and in vivo. Med Inflamm 1992;1:397-401.
Tavares-Murta BM, Cunha FQ, Ferreira SH. The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide production. Br J Pharmacol, in press.
